/
COLL
$35.98-$0.61 (-1.67%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.2B
32M shares
52-week range
$29.19 – $50.79
31% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$12.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $280.4M | $296.7M | $310.0M | $276.9M | $463.9M | $566.8M | $631.4M | $780.6M |
| Cost of revenue | $165.7M | $193.7M | $130.2M | $126.3M | $254.4M | $240.6M | $254.1M | $317.3M |
| Gross profit | $114.7M | $103.0M | $179.8M | $150.6M | $209.5M | $326.2M | $377.3M | $463.3M |
| Gross margin | 40.9% | 34.7% | 58.0% | 54.4% | 45.2% | 57.5% | 59.8% | 59.3% |
| R&D | $8.7M | $10.3M | $9.8M | $9.5M | $4.0M | $0 | $0 | $0 |
| Operating income | −$20.7M | −$23.7M | $56.2M | $17.6M | $33.3M | $167.0M | $169.9M | $187.1M |
| EBITDA | $91.9M | −$6.3M | $118.0M | $86.6M | $173.3M | $308.3M | $341.7M | $401.0M |
| Net income | −$39.1M | −$22.7M | $26.8M | $71.5M | −$25.0M | $48.2M | $69.2M | $62.9M |
| Net margin | -14.0% | -7.7% | 8.6% | 25.8% | -5.4% | 8.5% | 11.0% | 8.1% |
| EPS (diluted) | -1.19 | -0.24 | 0.76 | 1.86 | -0.74 | 1.29 | 1.86 | 1.73 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $873M | $7.78 | $7.50–$8.14 | 3 |
| 2027 | $866M | $7.51 | $6.33–$8.98 | 3 |
| 2028 | $834M | $6.56 | $6.10–$6.96 | 1 |
| 2029 | $909M | $9.37 | $8.70–$9.94 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$652.66
Price
$35.98
Implied upside
+1714%
Peer comparison
Collegium Pharmaceutical, Inc. Common Stock
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
www.collegiumpharma.com- Employees
- 423
- IPO / List date
- May 7, 2015
- HQ
- STOUGHTON, MA
Held by traders on TradeandTell
No one on the platform currently holds COLL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,469,449 | $48.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded COLL yet.
